Tri-Lo-Marzia is contraindicated in women with risk factors for venous thromboembolism and carries a 2-6 fold increased risk of pulmonary embolism compared to non-users.
Absolute Contraindications for Tri-Lo-Marzia
Tri-Lo-Marzia (norgestimate/ethinyl estradiol) must not be prescribed if the patient has any of the following 1:
- Personal history of deep vein thrombosis or pulmonary embolism (past or present)
- Inherited or acquired thrombophilia (Factor V Leiden, prothrombin mutation, protein C/S deficiency, antithrombin deficiency)
- Age >35 years who smokes
- Uncontrolled hypertension
- Diabetes with vascular complications
- Migraine with aura (any age) or any migraine if age >35
- Prolonged immobilization or major surgery planned
Quantifying the PE Risk
The baseline risk of VTE in young women not using hormonal contraception is 0.3-0.5 per 10,000 woman-years 2. Combined oral contraceptives increase this risk 3-6 fold to approximately 3-9 per 10,000 woman-years 3.
Norgestimate specifically (the progestin in Tri-Lo-Marzia) carries a lower VTE risk compared to third-generation progestins. Studies show norgestimate has a VTE risk similar to levonorgestrel (the lowest-risk progestin), with an incidence of approximately 30.6 per 100,000 woman-years 4. This is significantly lower than desogestrel (53.5 per 100,000) or drospirenone-containing pills 4, 5.
Risk Amplification with Additional Factors
The thrombogenic effect multiplies dramatically when combined with other risk factors 6:
- Inherited thrombophilia: Risk multiplied by 5-16 fold on top of the COC baseline risk 6
- Age >40 years: Significantly increased risk 6
- Obesity: Additive risk 6
- First year of use: Highest risk period 6
- Smoking: Independent PE risk factor that compounds COC risk 2
Clinical Decision Algorithm
If the patient has ANY of the following, do NOT prescribe Tri-Lo-Marzia:
- Personal history of VTE (DVT/PE)
- Known thrombophilia
- First-degree relative with VTE before age 60
- Age >35 + smoking
- Recent major surgery or prolonged immobilization planned
Alternative contraceptive options for women with VTE risk factors 6:
- First-line: Copper IUD (no hormones, no VTE risk)
- Second-line: Progestin-only methods
Important Caveats
Screening for thrombophilia is NOT routinely recommended before prescribing COCs unless there is a first-degree family history of VTE before age 60 6. If screening is indicated, test for: PT, aPTT, antithrombin, protein C, protein S, Factor V Leiden, and prothrombin 20210A mutation 6.
Superficial venous thrombosis alone does not contraindicate hormonal contraception 6.
The 2019 ESC guidelines emphasize that oral contraceptives are the most frequent VTE risk factor in women of reproductive age 3, and third-generation progestins (desogestrel, gestodene) carry 50-80% higher VTE risk than levonorgestrel 8. Norgestimate, while technically "third-generation," behaves more like second-generation levonorgestrel in terms of VTE risk 4, 9, 10.
For context: Pregnancy itself carries a VTE risk of 5-20 per 10,000 woman-years, and the postpartum period carries 40-65 per 10,000 woman-years 8—substantially higher than any COC.